Literature DB >> 23812199

Successful treatment of a patient with multicentric Castleman's disease who presented with thrombocytopenia, ascites, renal failure and myelofibrosis using tocilizumab, an anti-interleukin-6 receptor antibody.

Hiroshi Kawabata1, Shin-ichi Kotani, Yumi Matsumura, Tadakazu Kondo, Tatsuya Katsurada, Hironori Haga, Norimitsu Kadowaki, Akifumi Takaori-Kondo.   

Abstract

We herein describe an unusual case of multicentric Castleman's disease accompanied by thrombocytopenia, ascites, renal failure and myelofibrosis in a Japanese woman. The patient was initially diagnosed as having myelodysplastic syndrome with myelofibrosis. The general condition of the patient deteriorated rapidly; however, treatment with tocilizumab, an anti-interleukin-6 receptor antibody, together with corticosteroids dramatically improved her symptoms. The clinical features of this case were similar to those of three cases previously reported by Takai et al. (Rinsho Ketsueki, 2010, 51:320-5), which were determined to be thrombocytopenia, anasarca, fever, reticulin myelofibrosis and organomegaly (TAFRO) syndrome, a possibly distinct clinical entity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23812199     DOI: 10.2169/internalmedicine.52.9482

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  29 in total

1.  Successful treatment by tocilizumab without steroid in a very severe case of TAFRO syndrome.

Authors:  Tamami Fujiki; Suguru Hirasawa; Seishi Watanabe; Shunsuke Iwamoto; Ryoichi Ando
Journal:  CEN Case Rep       Date:  2017-03-07

2.  Aggressive TAFRO syndrome with reversible cardiomyopathy successfully treated with combination chemotherapy.

Authors:  Shunichiro Yasuda; Keisuke Tanaka; Ayako Ichikawa; Ken Watanabe; Emi Uchida; Masahide Yamamoto; Kouhei Yamamoto; Daisuke Mizuchi; Osamu Miura; Tetsuya Fukuda
Journal:  Int J Hematol       Date:  2016-05-31       Impact factor: 2.490

Review 3.  Multicentric Castleman disease: Where are we now?

Authors:  Hao-Wei Wang; Stefania Pittaluga; Elaine S Jaffe
Journal:  Semin Diagn Pathol       Date:  2016-05-16       Impact factor: 3.464

4.  TAFRO syndrome with refractory thrombocytopenia responding to tocilizumab and romiplostim: a case report.

Authors:  Shoko Noda-Narita; Keiichi Sumida; Akinari Sekine; Junichi Hoshino; Koki Mise; Tatsuya Suwabe; Noriko Hayami; Masayuki Yamanouchi; Toshiharu Ueno; Hiroki Mizuno; Masahiro Kawada; Rikako Hiramatsu; Eiko Hasegawa; Naoki Sawa; Kenmei Takaichi; Kenichi Ohashi; Takeshi Fujii; Yoshifumi Ubara
Journal:  CEN Case Rep       Date:  2018-02-21

5.  Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version.

Authors:  Yasufumi Masaki; Hiroshi Kawabata; Kazue Takai; Masaru Kojima; Norifumi Tsukamoto; Yasuhito Ishigaki; Nozomu Kurose; Makoto Ide; Jun Murakami; Kenji Nara; Hiroshi Yamamoto; Yoko Ozawa; Hidekazu Takahashi; Katsuhiro Miura; Tsutomu Miyauchi; Shinichirou Yoshida; Akihito Momoi; Nobuyasu Awano; Soichiro Ikushima; Yasunori Ohta; Natsue Furuta; Shino Fujimoto; Haruka Kawanami; Tomoyuki Sakai; Takafumi Kawanami; Yoshimasa Fujita; Toshihiro Fukushima; Shigeo Nakamura; Tomohiro Kinoshita; Sadao Aoki
Journal:  Int J Hematol       Date:  2016-03-18       Impact factor: 2.490

6.  Successful treatment of TAFRO syndrome, a variant type of multicentric Castleman disease with thrombotic microangiopathy, with anti-IL-6 receptor antibody and steroids.

Authors:  Shiho Fujiwara; Hiromi Mochinaga; Hirotomo Nakata; Koichi Ohshima; Masanori Matsumoto; Mitsuhiro Uchiba; Yoshiki Mikami; Hiroyuki Hata; Yutaka Okuno; Hiroaki Mitsuya; Kisato Nosaka
Journal:  Int J Hematol       Date:  2016-03-15       Impact factor: 2.490

7.  Durable remission with rituximab in a patient with an unusual variant of Castleman's disease with myelofibrosis-TAFRO syndrome.

Authors:  Preetesh Jain; Srdan Verstovsek; Sanam Loghavi; Jeffrey L Jorgensen; Keyur P Patel; Zeev Estrov; Luis Fayad; Naveen Pemmaraju
Journal:  Am J Hematol       Date:  2015-04-29       Impact factor: 10.047

Review 8.  Biologic Agents in the Treatment of Multicentric Castleman Disease.

Authors:  Konstantinos Kapriniotis; Savvas Lampridis; Sofoklis Mitsos; Davide Patrini; David R Lawrence; Nikolaos Panagiotopoulos
Journal:  Turk Thorac J       Date:  2018-10-01

9.  Complete Resolution of a Case of TAFRO Syndrome Accompanied by Mediastinal Panniculitis, Adrenal Lesion, and Liver Damage with Hyperbilirubinemia.

Authors:  Shiro Ono; Kiyomi Yoshimoto; Nobushiro Nishimura; Ryo Yoneima; Hiromasa Kawashima; Tadanao Kobayashi; Yoshiaki Tai; Makiko Miyamoto; Emiko Tsushima; Noritaka Yada; Kenji Nishio
Journal:  Intern Med       Date:  2020-11-16       Impact factor: 1.271

10.  International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.

Authors:  Frits van Rhee; Peter Voorhees; Angela Dispenzieri; Alexander Fosså; Gordan Srkalovic; Makoto Ide; Nikhil Munshi; Stephen Schey; Matthew Streetly; Sheila K Pierson; Helen L Partridge; Sudipto Mukherjee; Dustin Shilling; Katie Stone; Amy Greenway; Jason Ruth; Mary Jo Lechowicz; Shanmuganathan Chandrakasan; Raj Jayanthan; Elaine S Jaffe; Heather Leitch; Naveen Pemmaraju; Amy Chadburn; Megan S Lim; Kojo S Elenitoba-Johnson; Vera Krymskaya; Aaron Goodman; Christian Hoffmann; Pier Luigi Zinzani; Simone Ferrero; Louis Terriou; Yasuharu Sato; David Simpson; Raymond Wong; Jean-Francois Rossi; Sunita Nasta; Kazuyuki Yoshizaki; Razelle Kurzrock; Thomas S Uldrick; Corey Casper; Eric Oksenhendler; David C Fajgenbaum
Journal:  Blood       Date:  2018-09-04       Impact factor: 25.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.